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Abstract Integrin-induced focal adhesion kinase (FAK) phos- 
phorylation as well as insulin-like growth factor-I (IGF-I) and 
insulin activate MAP kinase. Since IGF-I or insulin have been 
suggested to affect FAK phosphorylation, we analyzed the role of 
FAK in IGF-I- or insulin-induced MAP kinase activation. 
Although MAP kinase was stimulated by IGF-I or insulin, 
FAK tyrosine phosphorylation remained unchanged in fibroblasts 
expressing normal or transiently elevated levels of IGF-I and 
insulin receptors. Further analysis in FAK deficient fibroblasts 
suggested that FAK impedes MAP kinase activation by IGF-I or 
insulin. 
© 1999 Federation of European Biochemical Societies. 
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1. Introduction 
The insulin-like growth factor-I receptor (IGF-IR) and the 
insulin receptor (IR) are related heterotetrameric protein ty- 
rosine kinases [1]. It is generally accepted that the main role of 
the IR is to regulate glucose homeostasis, whereas the IGF-IR 
is essential for cell proliferation, growth and differentiation 
[2 51. 
After binding of ligand to the extracellular subunit of the 
IGF-IR or the IR, the receptors become activated resulting in 
the phosphorylation of various substrates, including IRS-1, 
IRS-2 and Shc. Tyrosine-phosphorylated substrates ubse- 
quently bind SH2 domain-containing proteins, including the 
p85 subunit of PI 3' kinase, the adaptor proteins Grb2 and 
Nck, the tyrosine phosphatase Syp and the C-terminal Src 
kinase Csk [6 14]. Shc and Grb2 binding to the activated 
receptor leads to the activation of the Ras-MAP kinase signal- 
ing pathway [15,16]. 
The focal adhesion kinase (FAK) is a non-receptor p otein 
tyrosine kinase that plays an important role in cell adhesion 
and motility [17,18]. In response to integrin activation, FAK 
becomes phosphorylated on several tyrosine residues and 
binds the SH2 domains of Src and Fyn [19,20]. These kinases 
phosphorylate FAK on tyrosine 925, which then binds the 
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Grb2 SH2 domain, thereby linking the integrln signaling path- 
way to the Ras-MAP kinase pathway [21-23]. 
Previous tudies of the effects of insulin and IGF-I on FAK 
tyrosine phosphorylation have produced iffering results. Sev- 
eral studies showed that insulin induced a decrease in FAK 
tyrosine phosphorylation [12,24 28], whereas CHO cells ex- 
pressing endogenous levels of IR displayed negligible FAK 
dephosphorylation f llowing insulin stimulation [29]. With re- 
gard to the effect of IGF-I on FAK phosphorylation, Leven- 
thal et al. [30] found that IGF-I increased phosphorylation f 
FAK, whereas Pillay et al. [26] observed no effect of IGF-I. 
The differing results, although not necessarily incompatible, 
indicate that the effects of IGF-I and insulin on FAK phos- 
phorylation deserve further study. 
Because IGF-I and insulin may induce changes in FAK 
tyrosine phosphorylation and since FAK phosphorylation 
can lead to activation of the Ras-MAP kinase pathway, we 
studied whether IGF-I- or insulin-induced FAK phosphoryl- 
ation contributes to MAP kinase activation. Although FAK 
tyrosine phosphorylation did not change following IGF-I or 
insulin stimulation i  adherent fibroblasts, MAP kinase activ- 
ity was stimulated. Similar results were observed after transi- 
ent overexpression f the IGF-IR or the IR. However, fibro- 
blasts stably expressing high levels of IGF-IR showed 2- to 
3-fold increases in FAK tyrosine phosphorylation after IGF-I 
stimulation. In this situation the time courses of MAP kinase 
activation and FAK phosphorylation were not compatible 
with a direct effect of FAK on MAP kinase activation. More- 
over, in cells lacking FAK protein, MAP kinase activity was 
not reduced but rather increased by IGF-I or insulin. Thus, 
IGF-I- or insulin-induced MAP kinase stimulation is inde- 
pendent of FAK phosphorylation a d activation. 
2. Materials and methods 
2.1. Cell lines and vectors 
pCLXSN-hIGF-IR and pCLXSN-hIR were constructed by sub- 
cloning human IGF-IR cDNA from pRLDN vector and human IR 
cDNA from pBluescript-SK- into the pCLXSN vector. Both vectors, 
pRLDN-IGF-IR and pBluescript-SK+-hIR, were kindly provided by 
Dr. J.M.G. Olefsky (University of California, San Diego). 
The Src / mouse fibroblast cell line, Src 1S, and its wild-type 
counterpart, Src 8S, both spontaneously immortalized [31,32], were 
kindly provided by Dr. P. Soriano (Fred Hutchinson Cancer Research 
Center). The FAK --/-- mouse fibroblast cell line and its wild-type 
counterpart were kindly provided by Dr. D. Schlaepfer (The Scripps 
Research institute). 
2.2. Antibodies 
Anti-FAK rabbit polyclonal antibody was kindly provided by Dr. 
D. Schlaepfer (The Scripps Research Institute). Antiphosphotyrosine 
antibody (4G10) was from UBI (New York), the hybridoma for the 
monoclonal antibody to the hemagglutinin epitope tag (anti-HA, 
MAbl2CA5) was kindly provided by Dr. I. Wilson (The Scripps 
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Research Institute), anti-JR [3-subunit antibody was from Santa Cruz 
Biotechnology, Inc., the hybridoma for the monoclonal peptide anti- 
body directed against amino acids 2-17 of vSrc was from Microbio- 
logical Associates, and anti-Src hybridoma MAb327 was a generous 
gift from Joan Brugge [33]. 
Antibody to the IGF-IR was prepared by immunizing New Zealand 
white rabbits with a peptide corresponding to the C-terminal 14 ami- 
no acids of the ]3-subunit of the human IGF-IR (KNER- 
ALPLPQSSTC), cross-linked to keyhole limpet haemocyanin with 
glutaraldehyde. Affinity-purified antibodies were prepared using a col- 
umn containing the peptide covalently coupled to cyanogen bromide- 
activated Sepharose beads (Pharmacia). The rabbit polyclonal anti- 
body raised against he last 14 amino acids of the [3-subunit of the 
human IGF-IR immunoprecipitated a protein of about 97 kDa, the 
expected size of the human IGF-IR [3-subunit, from human 293 cells 
(data not shown). The specificity of the ]3-subunit antibody was veri- 
fied by peptide competition (data not shown). 
2.3. Immunoprecipitation 
Cells were incubated in Dulbecco's modified Eagle's medium sup- 
plemented with 0.1% calf serum for 18 h before stimulation with LR3- 
IGF-I (JRH Biosciences) or insulin (Sigma). Cells were lysed in RIPA 
buffer [34] modified by the addition of 10 U/ml aprotinin, 50 mM 
NaF, 1 mM phenylmethylsulfonyl fluoride, 20 ~tg/ml leupeptin, 1mM 
sodium orthovanadate, 0.5 mM dithiothreitol at 4°C. Lysates were 
precleared with formalin-fixed Staphylococcus aureus (Pansorbin) 
(Calbiochem) by centrifugation at 4°C for 20 min at 14000 rpm. 
Similar amounts of lysate (about 1 ml), adjusted to contain equal 
amounts of protein (0.5 1.0 mg), were incubated with 1 gg of anti- 
body for 2 h at 4°C. Protein A-agarose (Regpligen) was added for 1 h 
at 4°C and washed three times with lysis buffer at 4°C. Immune 
complexes were boiled and separated on a 10% SDS acrylamide gel. 
2.4. lmmunoblott&g 
After gel electrophoresis, proteins were transferred to an Immobi- 
lon polyvinylidene fluoride membrane (Millipore). The membrane was 
blocked overnight at 4°C in TBS-T (50 mM Tris-HC1 pH 8, 150 mM 
NaC1, 0.05% Tween 20) containing 5% bovine serum albumin. The 
membrane was incubated with primary antibodies at room temper- 
ature for 2 h, washed and incubated with horse-radish peroxidase- 
conjugated secondary antibody or 125I-protein A for 1 h. Antibodies 
were detected by enhanced chemiluminescence (Amersham Pharmacia 
Biotech) or autoradiography. 
2.5. In vitro kinase assay 
FAK in vitro kinase assays were performed as previously described 
[23]. In vitro kinase assays of HA-tagged p44-Erkl MAP kinase were 
done as previously reported [35]. 
3. Results and discussion 
in vitro kinase assay. As shown in Fig. 1C, the incorporation 
of 32p into FAK was unchanged by stimulation with IGF- I  or 
insulin. Thus, in these adherent mouse fibroblasts, FAK acti- 
vation, indicated by increased tyrosine phosphorylat ion or 
tyrosine kinase activity, is not involved in IGF- I -  or insulin- 
induced MAP kinase activation. 
3.2. FAK  pho~spholTlation is increased by IGF-I or insulin 
stimulation of  fibroblasts stably but not transiently 
overexpressing the IGF-IR or the IR 
Previous studies showed that treatment with insulin induced 
FAK dephosphorylat ion in cell lines expressing high levels of 
IR [12,24~29]. To test whether the response of FAK to IGF- I  
or insulin stimulation was different in cells expressing elevated 
levels of the receptors, we overexpressed the IGF- IR  and the 
IR using retroviral infection. Human 293 cells were cotrans- 
fected with the pCLXSN- IGF- IR  or IR vectors and the eco- 
tropic packaging vector, pCLeco. Retrovirus-containing me- 
dium was harvested 48 h after transfection and transferred to 
the 8S mouse fibroblasts. Infection efficiency varied from 50 to 
95% and the level of receptor expression increased dramati- 
cally after infection (data not shown). 
We then analyzed FAK tyrosine phosphorylat ion after 
st imulation with IGF- I  or insulin in the cells transiently over- 
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3.1. MAP kinase activation by IGF-I and insulin is" independent 
of  FAK  
To test the responses of the Src 8S fibroblasts to IGF- I  and 
insulin, MAP kinase activity was assayed. Cells transfected 
with an HA-tagged Erk l -MAP kinase gene were serum- 
starved and then stimulated with IGF- I  or insulin. Erk l -  
MAP kinase was immunoprecipitated from cell lysates, and 
the kinase activity was assayed in vitro using the C-terminus 
of the transcription factor Elk-l ,  fused to GST, as a substrate 
[35]. As shown in Fig. 1A, both IGF- I  and insulin stimulated 
MAP kinase activity 2- to 3-fold. 
In addition, we analyzed the level of tyrosine phosphoryl-  
ation of FAK following stimulation with IGF- I  or insulin. 
FAK was immunoprecipitated from lysates of stimulated 
and unstimulated cells and immunoblotted with the 4G10 
antiphosphotyrosine antibody. As shown in Fig. 1B, the rel- 
ative levels of FAK tyrosine phosphorylat ion were unchanged 
by stimulation with IGF- I  or insulin. To assess FAK tyrosine 
kinase activity, FAK immunoprecipitates were tested using an 
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Fig. 1. MAP kinase and FAK activation after IGF-I and insulin 
stimulation. A: Fibroblasts were treated for 5 min with the indi- 
cated amounts of IGF-I or insulin. Immunoprecipitated ErkI-MAP 
kinase was assayed by an in vitro kinase assay (upper panel). MAP 
kinase activity is given as incorporation of 32p into GST-EIk. HA- 
Erkl-MAP kinase was revealed by immunoblotting with anti-HA 
antibody (lower panel). B: Serum-starved fibroblasts were stimulated 
with IGF-I or insulin for 4 min. Immunoprecipitated FAK was re- 
vealed by immunoblotting with antiphosphotyrosine antibody 4G10 
(upper panel), and with the affinity-purified anti-FAK antibody 
(lower panel). C: In vitro kinase assay of FAK immunoprecipitates 
(upper panel) and FAK Western blot using 12SI-protein A (lower 
panel). 
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Fig. 2. FAK phosphorylation i  fibroblasts transiently and stably 
overexpressing the IGF-IR or the IR. A: Immunoprecipitated FAK 
from fibroblasts transiently overexpressing the IGF-IR or the IR 
was revealed by immunoblotting with antiphosphotyrosine a tibody 
4G10 (upper panel), and with the affinity-purified anti-FAK anti- 
body (lower panel). B: In vitro kinase assay of FAK immunopreci- 
pitates from the same cells as in A (upper panel) and FAK Western 
blot using 125I-protein A (lower panel). C: Immunoprecipitated 
FAK from fibroblasts tably overexpressing the IGF-IR was re- 
vealed by immunoblotting with antiphosphotyrosine a tibody 4G10 
(upper panel), and with the affinity-purified anti-FAK antibody 
(lower panel). 
expressing the receptors. As shown in Fig. 2A, the level of 
FAK tyrosine phosphorylation was unchanged after stimula- 
tion with IGF-I  or insulin. We further tested FAK autophos- 
phorylation activity in the overexpressing cells. As shown in 
Fig. 2B, FAK autophosphorylation activity was unchanged 
by stimulation with IGF- I  or insulin. 
Leventhal et al. [30] observed that IGF- I  increased FAK 
tyrosine phosphorylation i SH-SY5Y human neuroblastoma 
cells stably overexpressing the IGF-IR. To study whether 
mouse cells stably overexpressing the IGF- IR would behave 
differently from cells expressing normal levels, or transiently 
overexpressed levels of the IGF- I  receptor, we tested the effect 
of IGF-I  on NIH 3T3 mouse fibroblasts tably overexpressing 
the IGF-IR. Western blotting confirmed that the human IGF- 
IR was indeed overexpressed in these cells (data not shown). 
We then immunoprecipitated FAK after stimulation for either 
5 or 15 min with IGF-I  and analyzed tyrosine phosphoryl- 
ation by Western blotting with 4G10 antibody. As shown in 
Fig. 2C, although FAK protein levels remained similar during 
the experiment, an increase in FAK tyrosine phosphorylation 
was apparent at 5 and 15 min (2- and 3-fold, respectively). 
We conclude that FAK tyrosine phosphorylation i  re- 
sponse to IGF- I  or insulin was different depending on whether 
fibroblasts were transiently or stably overexpressing the IGF- 
IR or the IR. The lack of a change in FAK tyrosine phos- 
phorylation following stimulation was somewhat surprising in 
view of previous reports that FAK was dephosphorylated 
following insulin and phosphorylated following IGF-I  treat- 
ment in several cell types. However, our results are in agree- 
ment with a report by Konstantopoulos et al. [29] who ob- 
served differences in FAK phosphorylation i  cells expressing 
endogenous or stably elevated levels of IR. 
3.3. Src does not affect FAK phosphorylation following IGF-I  
or insulin stimulation 
Src is required in vivo for the phosphorylation of FAK 
tyrosine 925 [22], the Grb2 SH2 domain binding site, suggest- 
ing a Src-dependent MAP kinase activation after integrin 
stimulation [23]. Therefore, to analyze whether S c is required 
for FAK tyrosine phosphorylation after IGF- I  or insulin, we 
tested MAP kinase activity and FAK tyrosine phosphoryl- 
ation and activity following IGF-I  and insulin stimulation in 
fibroblasts with a targeted isruption of the Src gene [31,32]. 
These Src - / -  fibroblasts were expressing either physiological 
levels or transiently overexpressed IGF- IR or IR, and FAK 
@rosine phosphorylation and kinase activity were tested as 
described above. We observed that increasing concentrations 
of IGF-I  or insulin stimulate MAP kinase activity in Src - / -  
fibroblasts (Fig. 3A) as we previously described for the wild- 
type control fibroblasts (see Fig. 1A). Again, FAK tyrosine 
phosphorylation and kinase activity remained unchanged 
after IGF-I  or insulin stimulation (Fig. 3B and C). Moreover, 
we observed that the levels of FAK phosphorylation and 
FAK kinase activity were similar to the ones we observed in 
fibroblasts expressing Src. Thus, there is no difference in FAK 
tyrosine phosphorylation and activation between Src deficient 
and normal fibroblasts following hormone stimulation. This 
suggests that Src does not affect FAK phosphorylation and 
MAP kinase activation following IGF-I  or insulin. 
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Fig. 3. Role of Src in FAK phosphorylation a d activity after stim- 
ulation with IGF-I or insulin. Src deficient fibroblasts were used for 
these experiments. A: Same experiment as Fig. 1A done in parallel. 
B and C: Same experiments as Fig. 1B and Fig. 2A, and Fig. 1C 
and Fig. 2B, done in parallel. 
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periments. Although we could not confirm that FAK might 
repress MAP kinase activity, we can conclude from our results 
that FAK does not contribute to IGF-I-  or insulin-induced 
MAP kinase activation. 
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Fig. 4. Map kinase activation after IGF-I stimulation. A: Erkl- 
MAP kinase was assayed by an in vitro kinase assay using NIH 
3T3 fibroblasts stably overexpressing the IGF-IR (upper panel). 
HA-Erkl protein was revealed by immunoblotting with anti-HA 
antibody (lower panel). B: The same experiment as in A was done 
using FAK deficient cells or their wild-type control. 
3.4. Analysis" (~f FAK - / - -  cells and fibroblasts tably 
overexpressing the IGF-IR 
To determine whether the time course of IGF-I- induced 
FAK phosphorylation following treatment of cells stably 
overexpressing the IGF- IR  as described above was compatible 
with a role for FAK in MAP kinase activation, we compared 
the time course of FAK  tyrosine phosphorylation with the 
time course of MAP kinase activation. NIH 3T3 fibroblasts 
stably overexpressing the IGF- IR  were transfected with MAP 
kinase. Then, MAP kinase was immunoprecipitated from cells 
stimulated for various times with IGF-I. MAP kinase activity 
was tested in an in vitro kinase assay using GST-Elk as sub- 
strate. GST-Elk phosphorylation was maximal at 2.5 rain of 
stimulation and returned to a basal level after 15 rain (Fig. 
4A). In contrast, FAK phosphorylation i creased between 5 
and l 5 rain after IGF- I  stimulation (see Fig. 2C). These differ- 
ences in kinetics of FAK phosphorylation and MAP kinase 
activation suggest that FAK does not play a direct role in 
MAP kinase activation. 
Finally, to further confirm that FAK does not contribute to 
MAP kinase activation by IGF- I  and insulin, we measured 
MAP kinase activity following IGF-I  (Fig. 4B) and insulin 
(Fig. 4C) stimulation of FAK  deficient fibroblasts and their 
wild-type control. Surprisingly, MAP kinase activity is not 
decreased but dramatically increased after IGF- I  as well as 
insulin stimulation in these cells. This observation suggests 
that FAK could repress MAP kinase activation by IGF-I 
and insulin. To confirm that FAK represses IGF-I-  and in- 
sulin-induced MAP kinase activity, we tried to re-introduce 
FAK into the FAK deficient cells either transiently or by 
stable expression. Unfortunately, we were unable to observe 
a reproducible decrease in MAP kinase activity in these ex- 
3.5. Conclusion 
Integrin activates MAP kinase in a FAK-dependent manner 
[21]. IGF- I  and insulin have been observed to produce differ- 
ent effects on FAK tyrosine phosphorylation [12,24-29], and 
both hormones activate MAP kinase after receptor activation. 
Accordingly, we studied the involvement of FAK  tyrosine 
phosphorylation i MAP kinase activation after IGF- I  or in- 
sulin stimulation of mouse fibroblasts. Although MAP kinase 
was activated after IGF- I  and insulin stimulation, the levels of 
FAK  tyrosine phosphorylation and kinase activity did not 
change following stimulation. However, in cells stably over- 
expressing the IGF- IR,  we observed an increase in FAK ty- 
rosine phosphorylation, in accordance with a previous report 
[30]. This may be an indirect effect, since the IGF- IR auto- 
phosphorylation was maximal after 5 rain and decreased by 
15 min, whereas FAK tyrosine phosphorylation was maximal 
at 15 min. 
We observed similar differences in the time courses of FAK  
phosphorylation and MAP kinase activation in cells stably 
overexpressing the 1GF-IR: MAP kinase activity was maxi- 
mal after 2.5 rain and decreased by 15 min, whereas FAK 
phosphorylation was maximal at 15 rain. If FAK  was situated 
upstream of MAP kinase in the signaling events following 
IGF-!  stimulation, one would expect that FAK activation 
would precede MAP kinase activation. These kinetics suggest 
that FAK is not involved directly in MAP kinase activation 
following stimulation by IGF-I.  
The absence of contribution of FAK  in MAP kinase acti- 
vation following IGF- I  and insulin is further confirmed by the 
results observed with the FAK deficient fibroblasts. If FAK  
participated in insulin- or IGF-I- induced MAP kinase activa- 
tion, one would expect that MAP kinase activation was de- 
creased in these cells following stimulation in comparison to 
their control fibroblasts. This was not the case, and we even 
observed an increase in MAP kinase activation in the FAK 
deficient cells, suggesting that FAK may repress insulin- and 
IGF-I- induced MAP kinase activity. However, further studies 
are needed to better characterize this cell line and analyze 
whether this increase is due to a constitutive MAP kinase 
activation suggested by the higher MAP kinase activity before 
stimulation (see Fig. 4B), or due to a FAK-specific mechanism 
of MAP kinase downregulation. 
In summary, we conclude that FAK does not contribute to 
MAP kinase activation following IGF- I  or insulin stimulation 
indicating that FAK is not involved in the physiological sig- 
naling through the IGF- IR or the IR in fibroblasts. 
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